Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 10;11:1758835919841233. doi: 10.1177/1758835919841233

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Characterization of sensitive PANC1 and resistant PANC1R cells in vitro and in vivo.

(a) Dose-response curves of PANC1 (blue) and PANC1R (red) cells display a reduced sensitivity to gemcitabine. Points and bars, mean values and SEM obtained from 10 independent experiments. (b) PANC1R cells induce significantly more tumours by subcutaneous engraftment (n = 36, 18 mice per arm) than PANC1 cells. (c) Tumours originating from PANC1R developed an evident tumour nodule faster. (d) Tumours of PANC1R origin resulted in poorer OS (Day 0 was set for each mouse individually based on reaching evident tumour volume of 100 mm³). Of note, groups in survival analysis were unequal due to poor engraftment success of PANC1 cells (n = 4 versus n = 7).

OS, overall survival; PANC1, gemcitabine-sensitive cell line; PANC1R, gemcitabine-resistant PANC1 cell line.